Literature DB >> 832511

Pharmacokinetic study of fosfomycin and its bioavailability.

R Cadórniga, M Diaz Fierros, T Olay.   

Abstract

The pharmacokinetics of fosfomycin in humans was studied in six young healthy volunteers after intravenous administration of 500 mg fosfomycin and after the same dose in oral administration in three different formulations. It was proven that fosfomycin follows a bicompartmental pattern, for which the disposition constants, the biological half-lives for the fast and slow phases, and the distribution constants were calculated. The renal excretion constant was evaluated making determinations of fosfomycin in the urine, and this constant together with the elimination constant allowed us to determine the extrarenal elimination. The concentration and quantity of the drug in the central and peripheral compartments were calculated and tabulated for different periods of time. An analogous behavior was obtained with the three formulations that were orally administered, with an average bioavailability of 37% in relation to the intravenous bioavailability, as evaluated by means of the accumulative renal excretion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832511     DOI: 10.1159/000222043

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  8 in total

Review 1.  Plasmid-encoded fosfomycin resistance.

Authors:  J E Suárez; M C Mendoza
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid.

Authors:  C Fernandez Lastra; E L Mariño; A Dominguez-Gil; J M Tabernero; A Gonzalez Lopez; M Yuste Chaves
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

3.  Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity.

Authors:  T Bergan
Journal:  Infection       Date:  1990       Impact factor: 3.553

4.  Fosfomycin kinetics after intravenous and oral administration to human volunteers.

Authors:  M Goto; M Sugiyama; S Nakajima; H Yamashina
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

5.  IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis.

Authors:  Zoe Kane; Silke Gastine; Christina Obiero; Phoebe Williams; Sheila Murunga; Johnstone Thitiri; Sally Ellis; Erika Correia; Borna Nyaoke; Karin Kipper; John van den Anker; Mike Sharland; James A Berkley; Joseph F Standing
Journal:  J Antimicrob Chemother       Date:  2021-06-18       Impact factor: 5.790

Review 6.  Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Authors:  Anneke Corinne Dijkmans; Natalia Veneranda Ortiz Zacarías; Jacobus Burggraaf; Johan Willem Mouton; Erik Bert Wilms; Cees van Nieuwkoop; Daniel Johannes Touw; Jasper Stevens; Ingrid Maria Catharina Kamerling
Journal:  Antibiotics (Basel)       Date:  2017-10-31

7.  Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection.

Authors:  Sander G Kuiper; Anneke C Dijkmans; Erik B Wilms; Ingrid M C Kamerling; Jacobus Burggraaf; Jasper Stevens; Cees van Nieuwkoop
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.758

8.  Fosfomycin as a potential therapy for the treatment of systemic infections: a population pharmacokinetic model to simulate multiple dosing regimens.

Authors:  Natalia V Ortiz Zacarías; Anneke C Dijkmans; Jacobus Burggraaf; Johan W Mouton; Erik B Wilms; Cees van Nieuwkoop; Daan J Touw; Ingrid M C Kamerling; Jasper Stevens
Journal:  Pharmacol Res Perspect       Date:  2018-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.